Net Loss Per Share Attributable to Common Stockholders (Tables)

6 Months Ended

Jun. 30, 2025

Earnings Per Share [Abstract]

Schedule of Calculation for Basic and Diluted Net Loss Per Share

The following table presents the calculation for basic and diluted net loss per share (in thousands, except share and per share data):

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Numerator:
Net loss	$	(42,843	)	$	(552,212	)	$	(110,880	)	$	(616,955	)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares		—			(11,540	)		—			(39,347	)
Cumulative undeclared dividends on Series C preferred shares		—			(668	)		—			(1,174	)
Net loss attributable to common stockholders	$	(42,843	)	$	(564,420	)	$	(110,880	)	$	(657,476	)
Denominator:
Weighted-average common shares outstanding, basic and diluted		173,381			82,325			171,960			72,930
Net loss per share attributable to common stockholders, basic and diluted	$	(0.25	)	$	(6.86	)	$	(0.64	)	$	(9.02	)

Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share

The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share for each period, as the impact of including them would have been anti-dilutive. As disclosed in Note 10, the Company issued a warrant for $100 million in shares of the Company’s Class A common stock. As per the terms of the warrant, potentially dilutive shares are based on the latest equity financing price. The warrant was terminated for no consideration on December 31, 2024.

	As of June 30,
	2025		2024
Stock options outstanding		—		210,000
Astrazeneca warrant		—		2,702,703
Deep 6 holdback liability		17,372		—
SEngine holdback liability		—		41,007
Unvested RSUs		6,670,364		6,683,129
Unvested RSAs		23,887		—
SEngine contingent consideration		—		35,000
Total potentially dilutive shares		6,711,623		9,671,839